Novo Nordisk Makes Wegovy® More Accessible to Patients with Updated Savings Program

Novo Nordisk Expands Wegovy® Savings Program

As of March 24, 2025, Novo Nordisk has announced significant changes to the Wegovy® savings program, which now allows eligible cash-paying patients to obtain Wegovy® (semaglutide) injections at a reduced cost of $499 per month. This offer applies to various dosages of Wegovy®, ensuring broader access to an effective treatment for obesity. Previously, the $499 price was only available through NovoCare® Pharmacy, but now patients can access these savings through any retail pharmacy of their choice.

Novo Nordisk's commitment to making innovative medicines accessible reflects its core mission to help individuals manage their health better. Dave Moore, the Executive Vice President at Novo Nordisk, emphasized the importance of this initiative in promoting weight management and overall health. This program empowers individuals dealing with obesity, giving them a pathway to pursue their health goals without the stress of exorbitant medical expenses.

Additionally, the updated Wegovy® savings program serves as a safeguard against potential risks posed by unregulated compounding pharmacies. By ensuring access to FDA-approved Wegovy®, Novo Nordisk provides greater peace of mind to both healthcare professionals and patients who rely on the efficacy and safety of these treatments. Patients can find more information at Wegovy.com.

Understanding the Savings Offer

The Wegovy® savings offer is designed specifically for cash-paying patients or those whose insurance plans do not cover obesity medications. Under this program, eligible patients can acquire a 28-day supply of Wegovy® for the fixed monthly fee of $499. This is a significant reduction from the previous cost of $650, making it more accessible to those who need it. Importantly, individuals enrolled in government-funded healthcare programs are not eligible for this specific offer.

For patients with commercial health insurance that covers Wegovy®, out-of-pocket costs may be reduced to as low as $0 per month. With a potential maximum savings of $225 for a 28-day supply, this option presents a compelling alternative for those struggling to manage obesity-related health issues.

The Role of NovoCare® Pharmacy

The NovoCare® Pharmacy plays a pivotal role in providing services to patients prescribed Wegovy®. Not only does it offer direct home delivery of Wegovy® prescriptions, but it also supports patients by facilitating benefit verification, sending refill reminders, and providing live assistance from a dedicated case manager. These services are designed to ease the burden on patients and ensure they have continuous access to their prescribed medication.

With the increased accessibility of Wegovy® through both retail and NovoCare® pharmacies, patients have more flexible options to acquire this essential medication.

About Wegovy®

Wegovy® (semaglutide) is an injectable prescription medication. When paired with a balanced diet and an increase in physical activity, it has been shown to significantly reduce the risk of severe cardiovascular events, such as heart attack or stroke, in adults with pre-existing heart conditions and obesity. For adolescents aged 12 and over, it provides an effective means of managing excess weight and related health complications.

However, potential users must be aware of the safety information surrounding Wegovy®. Serious side effects may include the development of thyroid tumors or pancreatitis. Users are advised to discuss any pre-existing health conditions with their healthcare provider before starting treatment.

Safety Information

Before using Wegovy®, individuals should consult a healthcare professional, especially if they have a history of pancreatitis, kidney problems, or mental health issues. The most common side effects associated with Wegovy® include nausea, diarrhea, and headache.

Novo Nordisk's commitment to providing effective treatment options while ensuring patient safety is reflected in their proactive measures and clear communication about all potential risks associated with Wegovy® usage. For further information about Wegovy®, users can refer to the Medication Guide and Prescribing Information available on the company’s website.

Conclusion

With the expansion of the Wegovy® savings program and the dedicated services provided by NovoCare® Pharmacy, Novo Nordisk is making significant strides in providing affordable, high-quality treatment options for individuals struggling with obesity. The company's ongoing commitment to patient well-being reinforces its position as a leader in healthcare solutions. For those interested, more details can be found on Novo Nordisk's official website or their health communication platforms.